T1	Participants 181 233	human immune response to hepatitis B surface antigen
T2	Participants 341 449	50 subjects receiving four doses of hepatitis B vaccine according to a 0, 1, 2, 12 month vaccination scheme.
T3	Participants 450 589	Twenty-three subjects were given a plasma-derived vaccine (Hevac B) and 27 received a recombinant HBsAg vaccine (yeast-derived; Engerix-B).
